Antibody capturing materials for downstream processing


Monoclonal antibodies (mAb) is one of the most rapidly growing segments of biopharmaceuticals i.e. the use of proteins as the active pharmaceutical ingredient. The market for mAb:s is presently ca. 20 billion USD per annum globally and is estimated to grow to more than 30 billion USD by 2010. The research on mAb:s is very broad and targets mainly cancer, autoimmune diseases, cardiac diseases and infectious diseases. However, for mAb:s presently reaching the market, therapy costs are high which can be ascribed mainly to insufficient production capacities. The major bottleneck in this context can be found in the downstream processing i.e. the unit operation steps encompassing purification of the mAb from the crude fermentation broth. These presently rely on the use of efficient and selective but expensive and labile biological receptors or less efficient and less selective but on the other hand less costly and more stable separation techniques. In order to overcome these limitations we have formed the AbCap consortium with partners from industry (Bibitec, Merck) and from universities (HU Berlin, University Duisburg Essen, Technical University Dortmund). Our technical goal is to develop, characterise, and implement a new generation of high performance separation materials, designed for the purification of biopharmaceutical antibodies and based on imprinted polymers, which will be specifically designed for this purpose.


Principal Investigators
Panne, Ulrich Prof. Dr. (Details) (Analytical Chemistry)

Duration of Project
Start date: 01/2009
End date: 12/2012

Last updated on 2021-06-01 at 15:13